1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 36,50€ (−2,98%). The median is 36,49€ (−3,00%).
| Buy |
13 |
| Hold |
17 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 468.81m | 3,57% |
| Gross profit | 298.25m | 5,16% |
| Net profit | 90.60m | 10,95% |
| EBITDA | 124.53m | 20,19% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 7.73b€ |
Number of shares | 206.25m |
52-week high/low | 49,65€ - 27,93€ |
Dividend yield | 0,82% |
Dividends TTM | 0,31€ |
Beta | 0,62 |
P/E ratio | 22,38 |
PEG ratio | 1,59 |
P/B ratio | 2,68 |
P/S ratio | 4,29 |
Company profile
| Name | QIAGEN |
| CEO | Thierry L. Bernard |
| Headquarters | Venlo,
li Netherlands |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 5.500 |
Deep Dive
Discover assets
Shareholders of QIAGEN also invest in the following assets
